Coadministration with the hepatitis C virus (HCV) NS3/4A protease inhibitors, boceprevir and telaprevir, may increase the systemic exposure to
fluticasone following intranasal administration or oral inhalation. Boceprevir and telaprevir are potent inhibitors of CYP450 3A4. Since fluticasone undergoes extensive first-pass and systemic metabolism via hepatic and intestinal CYP450 3A4, inhibition of the isoenzyme may significantly increase systemic bioavailability of the drug.